Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;32(7):381.
doi: 10.3390/curroncol32070381.

A Comparison of Radiation and Alkylator-Based Conditioning Therapy Regimens for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Clinician's Perspective

Alejandro Marinos Velarde  1 , Julio Alvarenga Thiebaud  1 , Yazan Madanat  1 , Amir Toor  1
Affiliations
Review

A Comparison of Radiation and Alkylator-Based Conditioning Therapy Regimens for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Clinician's Perspective

Alejandro Marinos Velarde et al. Curr Oncol. .

Abstract

Despite significant advancements in the treatment of acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with primary refractory AML, those with relapsed disease and for patients who are in first complete remission where the disease has high risk cytogenetic and/or molecular features that increase relapse risk [...].

Keywords: acute myeloid leukemia; allogeneic stem cell transplantation; conditioning; myeloablative; reduced intensity conditioning.

PubMed Disclaimer

Conflict of interest statement

Y.M. has received honoraria/consulting fees from Servier, BMS, Kura Oncology, BluePrint Medicines, Geron, OncLive and MD Education, Targeted Oncology, Curio science, and Medscape Live. Y.M. participated in advisory boards and received honoraria from Stemline Therapeutics, Blueprint Medicines, Taiho Oncology, SOBI, Rigel Pharmaceuticals, Geron, Cogent Biosciences, and Abbvie. Y.M. received travel reimbursement from MD Education. None of these relationships were related to this work. A.M.V. has participated in advisory boards and received honoraria from Incyte. This was not related to this work. J.A.T. and A.T. declare no conflicts of interest.

Figures

Figure 1
Figure 1
TMLI 15 Gy dose distribution example.
Figure 2
Figure 2
Our approach to allogeneic stem cell transplantation for acute myeloid leukemia. The choice of conditioning is based on AML risk, the patient’s fitness, and the expected toxicity of the regimen. This figure intuitively outlines the most common conditioning regimens used at our institution. The horizontal arrows represent the applicability of each conditioning regimen based on ELN 2022 risk, and the vertical arrows correlate with the expected regimen toxicity.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Döhner H., Wei A.H., Appelbaum F.R., Craddock C., DiNardo C.D., Dombret H., Ebert B.L., Fenaux P., Godley L.A., Hasserjian R.P., et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–1377. doi: 10.1182/blood.2022016867. - DOI - PubMed
    1. Appelbaum F.R. Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. Am. Soc. Clin. Oncol. Educ. Book. 2014;34:e327–e333. doi: 10.14694/EdBook_AM.2014.34.e327. - DOI - PubMed
    1. Vriesendorp H.M. Aims of conditioning. Exp. Hematol. 2003;31:844–854. doi: 10.1016/S0301-472X(03)00229-7. - DOI - PubMed
    1. Scott B.L., Pasquini M.C., Fei M., Fraser R., Wu J., Devine S.M., Porter D.L., Maziarz R.T., Warlick E., Fernandez H.F., et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant. Cell. Ther. 2021;27:483.e1–483.e6. doi: 10.1016/j.jtct.2021.02.031. - DOI - PMC - PubMed
    1. Hourigan C.S., Dillon L.W., Gui G., Logan B.R., Fei M., Ghannam J., Li Y., Licon A., Alyea E.P., Bashey, et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J. Clin. Oncol. 2020;38:1273–1283. doi: 10.1200/JCO.19.03011. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources